1,586 Shares in Johnson & Johnson $JNJ Purchased by Acorns Advisers LLC

Acorns Advisers LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 1,586 shares of the company’s stock, valued at approximately $263,000.

Several other large investors have also recently bought and sold shares of the stock. Blue Rock Wealth Management LLC lifted its position in shares of Johnson & Johnson by 324.5% in the first quarter. Blue Rock Wealth Management LLC now owns 6,486 shares of the company’s stock valued at $1,076,000 after buying an additional 4,958 shares during the last quarter. Fortis Capital Advisors LLC lifted its position in shares of Johnson & Johnson by 411.7% in the first quarter. Fortis Capital Advisors LLC now owns 14,962 shares of the company’s stock valued at $2,481,000 after buying an additional 12,038 shares during the last quarter. Belpointe Asset Management LLC lifted its position in shares of Johnson & Johnson by 35.7% in the first quarter. Belpointe Asset Management LLC now owns 32,189 shares of the company’s stock valued at $5,338,000 after buying an additional 8,477 shares during the last quarter. Focus Partners Wealth lifted its position in shares of Johnson & Johnson by 15.4% in the first quarter. Focus Partners Wealth now owns 1,193,378 shares of the company’s stock valued at $197,910,000 after buying an additional 159,419 shares during the last quarter. Finally, Integrity Alliance LLC. lifted its position in shares of Johnson & Johnson by 239.0% in the first quarter. Integrity Alliance LLC. now owns 32,018 shares of the company’s stock valued at $5,310,000 after buying an additional 22,572 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on JNJ. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Citigroup lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Finally, Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $177.12 on Wednesday. The stock’s fifty day moving average price is $169.51 and its two-hundred day moving average price is $161.02. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $426.57 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company posted $2.82 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.